Men with less common types of prostate cancer have worse cancer control and greater need for radiation therapy after surgery. Oncologic and functional outcomes after robot-assisted radical ...

The FOXA1 protein is a potentially highly sensitive diagnostic marker for small cell carcinoma of the prostate and possibly ...

Significant progress in localized prostate cancer has been made, including improved and early detection, targeted biopsy, grading, disease prognostication, and outcome prediction, using imaging and ...

Prostate cancer stands as a prevalent threat to men's health, ranking second in cancer-related deaths in the United States. Each year, approximately 250,000 men in the U.S. receive a prostate cancer ...

Lab service utilizes Envision Science's proprietary biomarkers and technology with a goal of improving diagnosis and grading of prostate cancer The new, tissue-based test service is intended to ...

Microscopic glands of the prostate are segmented (colored) with the new deep-learning pipeline; the image shows a prostate cancer tissue volume, measuring roughly 1 x 1 x 2 mm in size. The prostate ...

Machine Learning Model Predicts Abnormal Lymphocytosis Associated With Chronic Lymphocytic Leukemia Artificial intelligence (AI) tools that identify pathologic features from digitized whole-slide ...

Among men with cribriform-positive disease at radical prostatectomy, only those with grade group 3 or higher disease or pT3b likely need adjuvant or early salvage treatment. Among men found to have ...

Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative interventional MRI (“iMRI”) procedures, is ...